Open access · CC-BY
via OpenAlex
CRISPR/Cas9-engineered mesenchymal stromal/stem cells and their extracellular vesicles: A new approach to overcoming cell therapy limitations
Ali Hazrati, Kosar Malekpour, Sara Soudi, Seyed Mahmoud Hashemi
Biomedicine & Pharmacotherapy · 2022 · ▲ 70 citations
Stem-cell exhaustion
Altered intercellular communication
Chronic inflammation
Gene therapy
Stem-cell therapy
Abstract
Cell therapy is one of the newest therapeutic approaches for treating tissue destruction diseases and replacing damaged parts in defective tissues. Among different cells, mesenchymal stem cells (MSCs) have received a lot of attention due to their advantages and desirable properties. Also, MSCs-derived secretome, which includes various growth factors, cytokines, and extracellular vesicles (EVs), is used in the treatment of different types of diseases. However, the application of MSCs in an intact form brings their functionality with limitations. For this reason, different methods are recommended to increase their efficiency and the extracellular vesicles derived from them. One of these methods is gene editing of these cells. Among the different techniques for MSCs gene editing, CRISPR/Cas9 can increase the therapeutic potential of MSCs in a targeted manner due to its advantages. In order to achieve the desired result, various genes have been manipulated in MSCs, including genes involved in stemness, aging, migration, proliferation, survival, and inflammatory responses. Engineering MSCs with this method affects the cells' characteristics, changes their cytokine and different growth factors secretions, and increases their therapeutic efficiency.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1016/j.biopha.2022.113943
- Canonical
- link ↗
- Fetched
- 2026-10-10 MST
Cite this
APA
Hazrati, A., Malekpour, K., Soudi, S., & Hashemi, S.M. (2022). CRISPR/Cas9-engineered mesenchymal stromal/stem cells and their extracellular vesicles: A new approach to overcoming cell therapy limitations. <em>Biomedicine & Pharmacotherapy</em>. https://doi.org/10.1016/j.biopha.2022.113943
Vancouver
Hazrati A, Malekpour K, Soudi S, Hashemi SM. CRISPR/Cas9-engineered mesenchymal stromal/stem cells and their extracellular vesicles: A new approach to overcoming cell therapy limitations. Biomedicine & Pharmacotherapy. 2022. doi:10.1016/j.biopha.2022.113943.
BibTeX
@article{ali2022CRISPR,
title = {CRISPR/Cas9-engineered mesenchymal stromal/stem cells and their extracellular vesicles: A new approach to overcoming cell therapy limitations},
author = {Ali Hazrati and Kosar Malekpour and Sara Soudi and Seyed Mahmoud Hashemi},
journal = {Biomedicine & Pharmacotherapy},
year = {2022},
doi = {10.1016/j.biopha.2022.113943},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Molecular Medicine Reports 2016
Open access · OA
Changes in mesenchymal stem cells following long-term culture in vitro
International Journal of Molecular Medicine 2017
Citation only
Senescence of mesenchymal stem cells (Review)
Cell Communication and Signaling 2020
Open access · CC-BY
Exosomal microRNAs derived from mesenchymal stem cells: cell-to-cell messages
Cellular and Molecular Immunology 2023
Open access · CC-BY
Immunomodulatory properties of mesenchymal stem cells/dental stem cells and their therapeutic applications
Bioengineering 2024
Open access · CC-BY
Role of Mesenchymal Stem/Stromal Cells (MSCs) and MSC-Derived Extracellular Vesicles (EVs) in Prevention of Telomere Length Shortening, Cellular Senescence, and Accelerated Biological Aging
Tissue and Cell 2021
Open access · CC-BY